Explore the long-term side effects of breast cancer treatment on your bones. Learn how your age and ethnic background impact your risk for developing osteopenia and osteoporosis, regardless of breast cancer history. Find out how chemotherapy, hormonal therapy and ovarian suppression affect your risk for bone fractures, and how tests such as DEXA scans help your doctor measure bone mineral density. Get tools to maintain and build bone strength, including exercise, nutrition, supplements and medicines. Available online only.
This activity is supported by an educational donation provided by Amgen Oncology. Download a PDF of Amgen's Bone Health In Focus: A Report about Breast Cancer’s Impact on Bones.
The guide was written with guidance from a team of healthcare professionals and women affected by breast cancer.
Download a sample PDF of the Guide to Understanding Bone Health.
The National Comprehensive Cancer Network changed its recommendations in December 2010 for women with metastatic breast cancer to the bone. NCCN now recommends that women with bone metastases should receive bone-targeting medicine to prevent bone fractures. The FDA approved denosumab (Xgeva) for this purpose in June 2010. It is a prescription medicine to treat bone complications in people with bone metastases from many types of solid tumors. It is given once every four weeks by injection. Please note that denosumab is FDA approved for metastatic breast cancer only, not early-stage breast cancer--the focus of LBBC's Guide to Understanding Bone Health.